CAMBRIDGE, Mass.--(BUSINESS WIRE)--Altus Pharmaceuticals Inc. (NASDAQ: ALTU), a biopharmaceutical company focused on oral and injectable protein therapeutics for gastrointestinal and metabolic disorders, today reported financial results for the quarter ended September 30, 2006. In addition, Altus Pharmaceuticals announced that its common stock was selected to be added to the NASDAQ Biotechnology Index (NBI) effective at the beginning of trading on Monday, November 20, 2006.
